Abstract Library

#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors

Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Korse C, Bonfrer J, van den Heuvel M, van Velthuysen M, Vincent A,

Keywords: Well- and moderately differentiated neuroendocrine tumors, proGastrin Releasing Peptide, chromogranin A, lung tumors,

#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors

Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Korse C, Bonfrer J, Taal B,

Keywords: neuroendocrine tumors, hepatic artery embolization, angiogenesis, necrosis, VEGF, Endothelin, pro-Endothelin, cytokeratin, MonoTotal,